GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:09 2024-09-06 EDT 5-day change 1st Jan Change
1,651.50 GBX +0.76% Intraday chart for GSK plc -0.33% +13.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Close Sharply Lower in Friday Trading; EU, Euro Area GDP Decelerate MT
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday MT
Sector Update: Health Care MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Ahead of Key Jobs Report MT
GSK's Phase 3 Trial of Nucala to Treat COPD Meets Primary Endpoint; Shares Rise 1% Pre-Bell MT
EXECUTIVE CHANGES: Invinity replaces CEO; Gulf Keystone chair dies AN
GSK hails positive results of Nucala clinical trials in lung disease AN
GSK: positive phase III data in COPD CF
GSK's Nucala Drug Cuts COPD Exacerbations in Late-stage Study MT
GSK's Asthma Treatment Shows Positive Results for Chronic Obstructive Pulmonary Disease DJ
EDX Medical Group Names New Chief Commercial Officer MT
Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary CI
GSK: to present its advances at the Vienna Congress CF
UK's FTSE 100 Joins European Rally on US Economy Surge MT
GSK: RSV vaccine indication extended in the EU CF
Stocks tick higher as investors prep for US GDP AN
GSK hails EU approval of RSV jab Arexy for 50-59 year olds AN
Stocks called up as market awaits US GDP figures AN
GSK's RSV Vaccine Receives Additional EU Approval MT
GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease CI
European Equities Close Mostly Higher in Wednesday Trading; Incoming HSBC CEO Mulls Staff Cuts MT
UK's FTSE 100 Index Ends Wednesday Session Little Changed MT
Mixed trade before Nvidia takes centre-stage AN
GSK plc's Nucala (Mepolizumab) Receives Approval in Japan for Treatment of Adults with Chronic Rhinosinusitis with Nasal Polyps CI
Chart GSK plc
More charts
Logo GSK plc
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Employees
70,212
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.52GBP
Average target price
19.68GBP
Spread / Average Target
+19.16%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. US FDA Expands Approval of GSK's Endometrial Cancer Treatment Jemperli
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW